Navigation Links
Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23

his cautionary statement and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    CONTACTS:

    OREXIGEN                    MEDIA                    INVESTORS

    Graham Cooper               Stephen Gendel           Jason Spark

    858 436-8600                212 918-4650             619 849-6005

CONTACT: Graham Cooper, +1-858-436-8600, Stephen Gendel, +1-212-918-4650Jason Spark, +1-619-849-6005, all for Orexigen(TM) Therapeutics, Inc.

Web site: http://www.Orexigen.com/

Ticker Symbol: (NASDAQ-NMS:OREX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis

Post Your Comments:
(Date:11/6/2009)...ll/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin ...roved reverse split of its common stock will take ...2009 on a 1-for-15 split-adjusted basis. Oxygen Bi...w symbol OXBT. The stock also will have a new CUSI...ctive. ,, "This reverse split was overwhelmingl...
(Date:11/6/2009)...PRNewswire/ -- In consultation with the U.S. Food ...lthcare, Division of McNEIL-PPC, Inc., is initiati...ct lots of TYLENOL® Arthritis Pain Caplet 100...AP. McNeil is initiating the recall after identify...with these lots that led to a small number of cons...
(Date:11/6/2009)...Therapeutics, Inc. announced today that it has fil....S. Securities and Exchange Commission (SEC) relat...s of its common stock. All shares of the common st...the Company. ,, Credit Suisse Securities (USA) ...Jaffray & Co. is acting as co-lead manager and...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 1Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 2Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 3Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 4Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 5Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 6Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 7Video 3A New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at G 55865 8SIGVARIS USA Extends Educational Efforts in Healthy Advices Skin Care Network 55860 1SIGVARIS USA Extends Educational Efforts in Healthy Advices Skin Care Network 55860 2SIGVARIS USA Extends Educational Efforts in Healthy Advices Skin Care Network 55860 3New Medical Technology Company CareFusion Spins Off From Cardinal Health Begins Trading on NYSE 55856 1New Medical Technology Company CareFusion Spins Off From Cardinal Health Begins Trading on NYSE 55856 2
...s; 11 Breast Cancer Studies; 9 Targeted,Agent Stud...all/ -- Lilly,Oncology will unveil 76 studies at t...Clinical Oncology (ASCO) in Chicago, Ill. from,Jun...ta on,GEMZAR(R) (gemcitabine HCl for injection), A...in, an investigational, oral, targeted,therapy. Th...
...ia--(BUSINESS WIRE)--May 23, 2007 -,ProtoKinetix I...studies conducted by ITTEC Stem, Inc. at the Unive...AAGP(TM) in the cryopreservation,process for stem ...ecule in the rapidly expanding stem cell industry....on human embryonic stem cells., Using standard cry...
Other Medicine Technology:Making Science Personal: Lilly Oncology to Unveil 76 Studies at,ASCO 2007 2ProtoKinetix's AAGP Dramatically Increases Recovery Rate of,Cryopreserved Stem Cells 2
(Date:11/8/2009)...are Reform Bill ,, Critical legislation would...ricans ,, CHICAGO, Nov. 7 /PRNewswire-USNewswi...atives passed by a vote of 220-215, critical healt...dicare for seniors and end discrimination by insur...ut of affordable health coverage. ,, The Affo...
(Date:11/7/2009)...re/ -- Karen Ignagni, President and CEO of America...lowing statement today on House passage of H.R. 39...sive health care reform, and we have contributed t... of how health insurance is provided. Earlier this...n of pre-existing condition exclusions, no longer ...
(Date:11/7/2009)...ok (GA), Louis J. Goodman (TX), Palmer P. Jones (N...ov. 7 The American Medi... society executive leaders with achievement awards...als of the medical profession. The awards were pre...ing in Houston. ,, (Logo: http://www.newscom...
(Date:11/7/2009)...ponsibility to vigorously oppose abortion in healt...INGTON, Nov. 7 Ameri... following statement on the news that Cardinal Jus...ordable Health Care for America Act (H.R. 3962), p... abortion is voted upon. ,, "Our Catholic bish...
(Date:11/7/2009)...ty of America (PRSA) will bestow the distinguished...e president of Brand Strategy, Communications and ... PRSA,s 2009 International Conference in San Diego...llows is one of the profession,s highest individua...PRSA, and 2009 chair of the College of Fellows. "I...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3
...LIN, N.J., April 21 Pharmos Corporation (Pink S... a private placement of common stock and warrants....ares of common stock and warrants exercisable for ...year term, is $0.12 per share. , , The three purc...
...Los Angeles Exposition Park , , LOS ANGE...Dimes premier fundraising event that benefits all ... to survive and thrive. 11,000 walkers are expecte...les, CA this Saturday, April 25. , , (Logo: http...
... YORK, April 21 Carl Icahn announced today that h... Jr., Chairman of the Board and James Wilson, Lead...nc. (Nasdaq: AMLN ) concerning recent discussion...irman of the Board, James Wilson, Lead Independ...
... YORK, April 21 Immtech Pharmaceuticals, Inc. (NY...is reorganizing its R&D operations. This restr...nities based on the Company,s ongoing discovery pr...l Development & Chief Medical Officer is being...
...ng contradicts belief that process favors people i...hDay News) -- People with kidney failure who live ...t a kidney transplant than people in urban areas, ...d 2007. After about two years on the list, 122,785...
... finds fewer complications with electrophysiologis...-- Chances are you,ve never heard of electrophysio...now about if you are one of the 100,000 or so Amer...rly. And the incidence of in-hospital complication...
Other Medicine News:Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2Health News:Icahn Responds to Cook and Wilson 2Health News:Icahn Responds to Cook and Wilson 3Health News:Icahn Responds to Cook and Wilson 4Health News:Immtech to Reorganize Research and Development Operations 2Health News:Immtech to Reorganize Research and Development Operations 3Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Doctor's Training Affects Defibrillator Implant Results 2Health News:Doctor's Training Affects Defibrillator Implant Results 3
Hemmingway
Kerpel
Endocrette Endocervical Curette
London Endocervical Curette
Medicine Products: